|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S1
|
$72,918
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S2
|
$200,473
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S3
|
$234,000
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-10
|
$2,574,000
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-37S1
|
$218,356
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-37S2
|
$203,848
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-37S3
|
$86,197
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
5P30CA016059-37
|
$2,170,000
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
2P30CA014520-44
|
$4,590,130
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S1
|
$250,000
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S2
|
$136,232
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S3
|
$75,711
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S4
|
$31,772
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-43S1
|
$40,593
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
5P30CA014089-43
|
$6,268,475
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S1
|
$629,550
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S2
|
$200,000
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S3
|
$125,000
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
5P30CA134274-11
|
$2,266,216
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Hawaii Cancer Center CCSG
|
2P30CA071789-18
|
$1,913,800
|
HOLCOMBE, RANDALL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$379,286
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
|
1R01CA214912-01A1
|
$629,914
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
5R01CA197336-03
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblas
|
5K08CA194162-04
|
$168,264
|
SCHNEPP, ROBERT
|
EMORY UNIVERSITY
|
|
The role of JMJD6 in MYC-mediated neuroblastoma
|
5R03CA212802-02
|
$89,750
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-07
|
$413,844
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma
|
1K08CA230223-01
|
$202,195
|
BOSSE, KRISTOPHER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-06
|
$347,563
|
SHOHET, JASON
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-10
|
$374,304
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Neuroblastoma with armed T cells
|
5R01CA182526-05
|
$1
|
LUM, LAWRENCE
|
UNIVERSITY OF VIRGINIA
|
|
Structural Variation in Neuroblastoma
|
5R01CA204974-03
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$587,337
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$602,021
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of Neuroblastoma
|
7R01CA215753-02
|
$340,118
|
FABBRI, MULLER
|
UNIVERSITY OF HAWAII AT MANOA
|
|
Role of m6A mRNA methylation in Neuroblastoma
|
5R21CA219352-02
|
$191,227
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
5R01CA180692-04
|
$606,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
N/A
|
National Institutes of Health
|
|
Research and Development of Effective Therapies for Patients with Rare Tumors
|
ZIA SC 010354
|
$646,556
|
Widemann, Brigitte
|
CCR (NCI)
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
ZIA BC 010788
|
$756,068
|
Thiele, Carol
|
CCR (NCI)
|
|
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers
|
1U01CA224766-01
|
$418,320
|
HEDRICK, CATHERINE
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
|
Preclinical Modelling and Therapeutic Development for Other Cancer Indications
|
ZIA BC 011848
|
$112,660
|
Sharan, Shyam
|
CCR (NCI)
|
|
Pediatric Preclinical Testing Consortium
|
5U01CA199287-04
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,462,501
|
Glod, John
|
CCR (NCI)
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$407,114
|
Thiele, Carol
|
CCR (NCI)
|
|
PARP-1 as a novel target for alpha-particle therapy in high-risk Neuroblastoma
|
1R01CA219006-01A1
|
$652,362
|
PRYMA, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
Novel ODC Inhibitor Phaseolotoxin in Neuroblastoma
|
1R21CA216867-01A1
|
$193,750
|
BACHMANN, ANDRE
|
MICHIGAN STATE UNIVERSITY
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
5R01CA197964-04
|
$352,710
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Myc - Transcription and Apoptosis
|
5R01CA051497-28
|
$382,892
|
DANG, CHI
|
WISTAR INSTITUTE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|